Search - tctmd.com

Displaying 21 - 29 of 29

Sort: Relevancy | Date

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

News Daily News

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

L.A. McKeown

October 10, 2023

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

News Daily News

Carpal Tunnel Syndrome Again Tied to Heart Failure: German Data

Caitlin E. Cox

July 19, 2023

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

L.A. McKeown

July 17, 2023

Presentation THT 2023

ATTR-CM is a serious and underrecognized cause of heart failure. This program will help raise awareness of the signs and symptoms of ATTR-CM, the role of cardiac health professionals in diagnosis, and a treatment option for patients with ATTR-CM

Presenter: Charles Dow

March 20, 2023

Presentation THT 2022

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Evaluating clinical findings to support earlier diagnosis and management

Presenter: Gregg Lanier

February 01, 2022

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Industry News

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

May 06, 2019

Advertisement

Evoque and Patisiran: A Tale of Two Regulatory Journeys

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Carpal Tunnel Syndrome Again Tied to Heart Failure: German Data

ATTRibute-CM Top-Line Results Favorable for Acoramidis

ATTR-CM is a serious and underrecognized cause of heart failure. This program will help raise awareness of the signs and symptoms of ATTR-CM, the role of cardiac health professionals in diagnosis, and a treatment option for patients with ATTR-CM

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Evaluating clinical findings to support earlier diagnosis and management

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content